Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams17.15.02.001; 19.02.03.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arterial thrombosis24.01.01.002--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Blepharitis06.04.04.001; 23.03.04.012--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Bronchial obstruction22.03.01.013--
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Catatonia19.11.01.001--Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.003--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages